OMER's largest institutional shareholder according to Yahoo finance is Ingalls & Snyder who held 1,060,885 shares on 12/31/12 but, as reported in an SC13g filing today, they now own 1,322,885 shares, or 5.1% of OMER's outstanding shares.
That's an increase of 262,000 shares in three months.
Nice to see Ingalls & Snyder increase their stake, as they are a very well managed NY Investment broker dealer. But the stock is still under distribution with negative money flow. Technically the chart is broken, though there is a positive divergence on MACD. Looking forward, I believe this a a good entry point with a 6 to 9 month outlook. Possible catalysts include 302 NDA and FDA acceptance of NDA (typically 60 days after filing), new patents issued, more clinical results and what I truly hope is a development partner on either PDE or MASP-2 drugs. Financing will continue to be an overhang, but at a $100 Million market cap, the stock is very under valued. Hopefully we get a nice turnaround story to talk about at the end of the year.